The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission

Leukemia and Lymphoma

Volumn 25, Issue 5-6, 1997, Pages 469-478

  Blaise, Didier ^a   Attal, Michel ^b   Pico, Jose Luis ^c   Reiffers, Josy ^d   Stoppa, Anne Marie ^a   Bellanger, Coralie ^e   Molina, Lysiane ^f   Nedellec, Gerard ^g   Vernant, Jean Paul ^h   Legros, Michel ⁱ   Gabus, Raul ^a   Huguet, Françoise ^b   Brandely, Maud ^k   Hercend, Thierry ^j   Olive, Daniel ^a   Maraninchi, Dominique ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b CHU PURPAN   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HÔPITAL MICHALLON   (France)

^g University of Paris Descartes   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ Jean Perrin Centre   (France)

^j Assoc pour la Rech sur le Cancer   (France)

^k Rounel Liclaf   (France)

more..

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Autologous bone marrow transplantation; Immunotherapy; Interleukin 2

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT INTERLEUKIN 2; RU 49637; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 6444245790     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039034     Document Type: Article

References (43)

1. Zittoun, R. A., Mandelli, F , Willemze, R., De Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E , Visani, G., Papa, G., Caronia, F., Hayat, M., Stryckmans, P., Rotoli, B., Leoni, P., Peetermans, M. E., Dardene, M., Vegna, M. L., Petti, M. C., Solbu, G. and Suciu, S. (1995). Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia, N. Engl. J. Med., 332, 217-223.
2. Copelan, E. A. and McGuire, E. A. (1995). The biology and treatment of acute lymphoblastic leukemia in adults, Blood, 85, 1151-1168.
3. Horowitz, M. M., Gale, R. P., Sondel, P. M., Goldman, J. M., Kersey, J., Kolb, H. J., Rimm, A. A., Ringden, O., Rozman, C., Speck, B., Truitt, R. L., Zwaan, F. E. and Bortin, M. M (1990). Graft-versus-leukemia reactions after bone marrow transplantation, Blood, 75, 555-562.
4. Maraninchi, D., Gluckman, E., Blaise, D., Guyotat, D., Rio, B., Pico, J. L., Leblond, V., Michallet, M , Dreyfus, F. and Ifrah, N. (1987). Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukemias, Lancet, 2, 175-178.
5. Blaise, D., Olive, D., Michallet, M., Marit, G., Leblond, V. and Maraninchi, D. (1995). Impairment of leukaemia-free survival by addition of interleukin-2 receptor antibody to standard graft-versus-host prophylaxis, Lancet, 345, 1144-1146.
6. Laporte, J. P., Douay, L., Lopez, M , Labopin, M., Jouet, J. P., Lesage, S., Stachowiak, J., Fouillard, L., Isnard, F., Noel-Walter, M. P., Pene, F., Deloux, J., Van Den Akker, J., Grande, M., Bauters, F., Najman, A. and Gorin, N C. (1994). One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood, 84, 3810-3818.
7. Reiffers, J., Gaspard, M. H., Maraninchi, D., Michallet, M., Marit, G., Stoppa, A. M., Corront, B., David, B., Gastaut, J. A., Sotto, J. J., Braustet, A., Carcassonne, Y. and Hollard, D. (1989). Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial, Br. J. Haematol., 72, 57-63.
8. Martin, P. J., Hansen, J. A., Storb, R. and Thomas, E. D. (1987). Human marrow transplantation: An immunological perspective. Adv. Immunol.,40, 379-389.
9. Robertson, M. J. and Ritz, J. (1990). Biology and clinical relevance of human natural killer cells. Blood, 76, 2421-2438.
10. Hercend, T., Takvorian, T., Nowill, A , Tantravahi, R., Momgeon, P., Anderson, K. C., Murray, C., Bohuon, C., Ythier, A and Ritz, J. (1986). Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation, Blood, 67, 722-728.
11. Lotzova, E. (1992). Role of interleukin-2 activated MHC-non restricted lymphocytes in antileukemia activity and therapy, Leukemia and Lymphoma, 7, 15-28
12. Foa, R., Guarini, A , Tos, A. G., Cardona, S., Fierro, M. T., Meloni, G., Tosti, S., Mandelli, F. and Gavosto, F. (1991). Peripheral Blood and Bone Marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2 evidence of in vivo lymphokine activated killer cell generation, Cancer Research. 51, 964-968.
13. Rosenberg, A., Lotze, M. T., Muul, L M., Chang, A. E., Avis, F. P., Leitman, S , Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G and White, D. E. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukm-2 alone, N. Engl. J. Med., 316, 889-897.
14. Gisselbrecht, C., Maraninchi, D., Pico, J. L., Milpied, N., Coiffier, B., Divine, M., Tiberghien, P., Bosly, A., Tilly, H., Boulat, O. and Brandely, M. (1994) Interleukin-2 treatment in lymphoma: a phase II multicenter study Blood, 83, 2081-2085.
15. Blaise, D., Viens, P., Olive, D., Stoppa, A. M , Gabert, J., Pourreau, C N., Attal, M., Gaspard, M. H., Mannoni, P., Jasmin, C., Palmer, P., Franks, C., Michel, G., Mawas, C., Baume, D., Philip, T and Maraninchi, D. (1991). Recombinant interleukin-2 after autologous bone marrow transplantation: a pilot study in 19 patients, Eur. Cytokine Net., 2, 121-129.
16. Benyunes, M. C., Massumoto, C., York, A., Higuchi, C. M., Buckner, C. D., Thompson, J. A., Petersen, F B. and Fefer, A. (1993). Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia, Bone Marrow Transplantation, 12, 159-163.
17. Gottlieb, D. J., Prentice, H. G. and Heslop, H. E. (1989). Effects of recombinant interleukine-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy, Blood, 74, 2335-2342.
18. Hamon, M. D., Prentice, H. G., Gottlieb, D. J., Gottlieb, D J., Macdonald, I. D , Cunningham, J. M., Smith, O. P., Gilmore, M., Gandhi, L. and Collis, C. (1993) Preliminary report Immunotherapy with interleukin 2 after ABMT in AML, Bone Marrow Transplantation, 11, 399-401.
19. Bosly, A., Guillaume, T., Brice, P., Humblet, Y., Staquet, P., Doyen, C., Chatelain, B., Franks, C. R., Gisselbrecht, C. and Symann, M. (1992). Effects of escalading doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors, Exp. Hematol., 20, 962-968.
20. Costello, R., Blaise, D., Jacquemier, J., Monges, G., Stoppa, A. M., Viens, P., Olive, D., Bouabdallah, R., Brandely, M., Gastaut, J. A and Maraninchi, D. (1995). Induction of cutaneous graft versus host like reaction by recombinant IL-2 after autologous bone marrow transplantation, Bone Marrow Transplantation, 16, 199-200.
21. Gaspari, A A., Lotze, M. T., Rosenberg, S. A., Stern, J. B. and Katz, S. I. (1987). Dermatologic changes associated with interleukin 2 administration. J. Am. Med. Assoc., 258, 1624-1629.
22. Ettinghausen, S. E., Moore, J. G., White, D. E., Platanias, L., Young, N. S. and Rosenberg, S A. (1987). Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant IL2 m cancer patients. Blood, 6, 1654-1660.
23. Schwartentruber, D. J , White de Zweig, M. H., Weintraub, B. D. and Rosenberg, S. A. (1991) Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer. 68, 2384-2390
24. Vialettes, B., Guillerand, M. A., Viens, P., Stoppa, A. M., Baume, D , Sauvan, R., Pasquier, J., San Marco, M , Olive, D. and Maraninchi, D. (1993). Incidence rate risk and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies, Acta Endocrinol., 129, 31-38.
25. Murphy, P. M., Lane, H. C., Gallin, J. I. and Fauci, A. S. (1988). Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon gamma, Ann. Intern. Med., 108, 36-41.
26. Blaise, D., Stoppa, A. M., Viens, P., Sainty, D , Fossat, C., Miquel, M., Olive, D., Bouabdallah, R , Gabert, J., Baume, D and Maraninchi, D. (1992). Intensive immunotherapy with recombinant IL2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections, Bone Marrow Transplantation, 10, 193-195
27. Attal, M., Blaise, D., Marit, G., Payen, C., Michallet, M., Vernant, J P., Sauvage, C., Troussard, X., Nedellec, G , Pico, J. L , Huguet, F., Stoppa, A. M., Broustet, A., Sotto, J. J., Pris, J., Maraninchi, D. and Reiffers, J. Consolidation treatment of adult acute lymphoblastic leukemia a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant Interleukin-2 after autologous bone marrow transplantation, Blood, 86(4), 1619-1628.
28. Blaise, D., Olive, D., Stoppa, A. M., Viens, P., Pourreau, C., Lopez, M., Attal, M., Jasmin, C., Monges, G., Mawas, C., Mannoni, P., Palmer, P., Franks, C., Philip, T. and Maraninchi, D. (1990). Hematologic and Immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation, Blood, 76, 1092-1097.
29. Sykes, M., Abraham, V. S., Harty, N. W. and Pearson, D. A. (1993). IL2 reduces graft versus host disease and preserves a graft versus leukemia effect by selectively inhibiting CD4+ T cell activity, J. Immunol., 150, 197-205
30. Smith, K. A. Lowest dose interleukin-2 immunotherapy, Blood, 81, 1414-1423.
31. Atzpodien, J., Körfer, A., Franks, C. R., Poliwoda, H. and Kirchner, H. (1990). Home therapy with recombinant interleukin-2 and Interferon α2b in advanced human malignancies, Lancet, 335, 1509-1512.
32. Soiffer, R. J., Murray, C., Gonin, R. and Ritz, J. (1994). Effect of low dose interleukin-2 on disease relapse after T-cell depleted allogeneic bone marrow transplantation, Blood, 84, 964-971.
33. Weisdorf, D. J., Andersen, P. M., Blazar, B. R., Uckun, F. M., Kersey, J. H. and Ramsay, N. K. (1993). Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia: a phase I study. Transplantation, 55, 61-66
34. Brenner, M K. and Heslop, H. E. (1992). Immunotherapy of leukemia, Leukemia, 6, 76-79
35. Lehmann, F., Marchand, M., Hainaut, P., Pouillart, P., Sastre, X., Ikeda, H., Boon, T. and Coulie, P. G. (1995). Differences in the antigens recognized by cytolytic T cells on two succes sive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25, 340.
36. Foa, R. (1993). Does interleukm-2 have a role in the management of acute leukemia, J. Clin. Oncol., 11, 1817-1825.
37. Maraninchi, D., Blaise, D., Viens, P., Brandely, M., Olive, D., Lopez, M , Sainty, D , Marit, G., Stoppa, A. M., Reiffers, J., Gratecos, N., Bertau-Perez, P., Mannoni, P., Mawas, C., Hercend, T., Sebahoun, G. and Carcassonne, Y. (1991). High dose recombinant interleukin-2 and acute myeloid leukemias in relapse, Blood, 78, 2182-2187.
38. Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, A. G. and Mandelli, F. (1994). Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia, Blood, 84, 2158-2163.
39. Reittie, J. E., Gottlieb, D., Heslop, H. E., Leger, O., Drexler, H. G., Hazlehurst, G., Hoffbrand, A. V., Prentice, H. G. and Brenner, M. K. (1989). Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy, Blood, 73, 1351-1358.
40. Higuchi, C. M., Thompson, J. A., Cox, T., Lindgren, C. G., Buckner, C. D. and Fefer, A. (1989). Lymphokine activated killer function following autologous bone marrow transplantation for refractory hematological malignancies, Cancer Research, 49, 5509-5513
41. Fierro, M. T., Liao, X. S., Lusso, P., Bonferroni, M., Matera, L., Cesano, A., Lista, P., Arione, R., Forni, G. and Foa, R. (1988). In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity, Leukemia, 2, 50-54.
42. Brenner, M. K., Rill, D. R., Moen, R. C , Krance, C., Miro, J., Anderson, W. F. and Ihle, J. N. (1993). Gene marking to trace origin of relapse after autologous bone marrow transplantation, Lancet, 341, 85-86.
43. Fefer, A., Einstein, A. B., Thomas, D., Buckner, C. D., Clift, R. A., Glucksberg, H., Neiman, P. E. and Storb, R. Bone marrow transplantation for hematologic neoplasia in 16 patients with identical twins, The New Engl. J of Med., 290, 1389-1393.